REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study was to determine the current status of the Alzheimer’s disease treatments and diagnostics and assess the growth potential of this area over a 5-year period from 2009 to 2014.
Our key objective was to present a comprehensive analysis of the current pipeline of therapeutic and diagnostic technologies, analyze the market and forecast for Alzheimer’s therapeutics and diagnostics, along with outlining the key factors that will influence this therapeutic area in the next few years.
REASONS FOR DOING THIS STUDY
Alzheimer’s disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients climb and the frustration with lack of effective treatments grows. Though there are a number of marketed drugs approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, there are now numerous companies developing novel treatments. This report will review the programs in development and quantify the market opportunities in AD. This study aims to quantify where this market is heading and where the opportunities may lie.
SCOPE OF REPORT
The scope of this report is on the ethical pharmaceutical segment, diagnostics and imaging modalities. We have compiled a study of the market, and current and emerging modes of treatment. We present the market segment’s economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2009 to 2014. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will be of interest also to suppliers of products and services to this market area.
INTENDED AUDIENCE
The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this research report. We present an analysis, by each disease area, of the number of current patients. Then, based on our surveys, we analyze the potential applications for pharmaceuticals, and forecast markets for 2009 through 2014.
INFORMATION SOURCES
BCC surveyed approximately 50 companies to obtain data for this study. Included were drug development and diagnostics companies and medical professionals. We also spoke with patients affected by the memory and cognition diseases. In addition, we compiled data from current financial and trade information, and government sources.
ANALYST CREDENTIALS
Maura Lane Warner has 18 years of industry experience, as both a chemical engineer and market and business development executive in the pharmaceutical and biotechnology area. She has a BS in Chemical Engineering and an MBA in Marketing. Maura has also authored reports on Therapeutics for Memory and Cognition and Microfluidics.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
